Anders S Bjartell
Overview
Explore the profile of Anders S Bjartell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1044
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carlsson S, Lilja H, Vickers A, Bjartell A
Eur Urol
. 2024 Sep;
87(3):368-369.
PMID: 39327117
No abstract available.
2.
van Straten C, Caris C, Grimm M, Colombel M, Muilwijk T, Martinez-Pineiro L, et al.
Eur Urol Open Sci
. 2023 Oct;
56:15-24.
PMID: 37822514
Background: Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of...
3.
4.
Grimm M, van der Heijden A, Colombel M, Muilwijk T, Martinez-Pineiro L, Babjuk M, et al.
Eur Urol
. 2020 May;
78(5):690-698.
PMID: 32446864
Background: Intravesical instillation of bacillus Calmette-Guérin (BCG) is an accepted strategy to prevent recurrence of non-muscle-invasive bladder cancer (NMIBC) but associated with significant toxicity. Objective: NIMBUS assessed whether a reduced...
5.
6.
Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C, et al.
Eur Urol
. 2016 Aug;
71(2):151-154.
PMID: 27477525
Patient Summary: According to data from longer follow-up, enzalutamide continued to provide benefit over placebo in patients with metastatic castration-resistant prostate cancer.
7.
8.
Braun K, Sjoberg D, Vickers A, Lilja H, Bjartell A
Eur Urol
. 2015 May;
69(3):505-11.
PMID: 25979570
Background: A statistical model based on four kallikrein markers (total prostate-specific antigen [tPSA], free PSA [fPSA], intact PSA, and human kallikrein-related peptidase 2) in blood can predict risk of Gleason...
9.
Bostrom P, Bjartell A, Catto J, Eggener S, Lilja H, Loeb S, et al.
Eur Urol
. 2015 Apr;
68(6):1033-44.
PMID: 25913390
Context: Given the highly variable behavior and clinical course of prostate cancer (PCa) and the multiple available treatment options, a personalized approach to oncologic risk stratification is important. Novel genetic...
10.